Initial treatment of transplant-eligible patients in multiple myeloma.

Item

http://www.wikidata.org/entity/Q38176061

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Initial treatment of transplant-eligible patients in multiple myeloma.

@en

type

Item

label

Initial treatment of transplant-eligible patients in multiple myeloma.

@en

prefLabel

Initial treatment of transplant-eligible patients in multiple myeloma.

@en

P1476

Initial treatment of transplant-eligible patients in multiple myeloma.

@en

P2093

Laura Rosiñol

http://www.w3.org/2001/XMLSchema#string

Phillipe Moreau

http://www.w3.org/2001/XMLSchema#string

Shaji Kumar

http://www.w3.org/2001/XMLSchema#string

P2860

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study.

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.

P304

43-53

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/17474086.2014.871200

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Michele Cavo

P577

2014-01-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24392968

http://www.w3.org/2001/XMLSchema#string